DrugPatentWatch Database Preview

Details for Patent: 8,754,257

« Back to Dashboard

Which drugs does patent 8,754,257 protect, and when does it expire?

Patent 8,754,257 protects AURYXIA and is included in one NDA.

This patent has eighty-two patent family members in twenty countries.

Summary for Patent: 8,754,257

Title:	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Abstract:	The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
Inventor(s):	Chan; Keith (Rockville, MD), Town; Winston (Hong Kong, CN)
Assignee:	Panion & BF Biotech Inc. (TW)
Application Number:	13/661,558
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,754,257
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,754,257
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,754,257

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014		RX	Yes	Yes			Y

International Family Members for US Patent 8,754,257

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004213819
Australia	2006279333
Australia	2007210090
Australia	2007210096
Canada	2516471
Canada	2619591